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Irreversible electroporation (IRE) is an emerging cancer treatment that utilizes
non-thermal electric pulses for tumor ablation. The pulses are delivered through
minimally invasive needle electrodes inserted into the target tissue and lead to cell
death through the creation of nanoscale membrane defects. IRE has been shown to
be safe and effective when performed on tumors in the brain, liver, kidneys, pan-
creas, and prostate that are located near critical blood vessels and nerves. Accurate
treatment planning and prediction of the ablation volume require a priori knowl-
edge of the tissue-specific electric field threshold for cell death. This study
addresses the challenge of defining an electric field threshold for human prostate
cancer tissue. Three-dimensional reconstructions of the ablation volumes were cre-
ated from one week post-treatment magnetic resonance imaging (MRIs) of ten
patients who completed a clinical trial. The ablation volumes were incorporated
into a finite element modeling software that was used to simulate patient-specific
treatments, and the electric field threshold was calculated by matching the ablation
volume to the field contour encompassing the equivalent volume. Solutions were
obtained for static tissue electrical properties and dynamic properties that
accounted for electroporation. According to the dynamic model, the electric field
threshold was 5066 66V/cm. Additionally, a potentially strong correlation
(r¼0.624) was discovered between the electric field threshold and pre-treatment
prostate-specific antigen levels, which needs to be validated in higher enrollment
studies. Taken together, these findings can be used to guide the development of
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future IRE protocols.VC 2017 Author(s). All article content, except where otherwise
noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5005828
I. INTRODUCTION
Irreversible electroporation (IRE) is a non-thermal, soft tissue ablation modality1 that has
been used to treat a variety of tumors in the liver,2 kidneys,3 pancreas,4,5 and prostate.6–9 This
technique involves generating pulsed electric fields between electrodes that are inserted into or
around the region of interest. If the electric field is of sufficient strength and duration, cells die
through the creation of long-lasting nanopores in the plasma membrane.10 Because the mecha-
nism of cell death does not rely on extreme temperatures, IRE can be performed safely near
major blood vessels11 and nerves.12 Therefore, it is gaining momentum as a viable treatment
option for surgically inoperable tumors and an alternative to functionally limiting resection
procedures.
The first human IRE trials in the prostate were performed by Onik and Rubinsky.13
Following the placement of 4 electrodes in a square grid, a NanoKnife
VR
generator was used to
apply IRE pulses between all pairs, including the diagonals (six treatments). Immediately after
treatment, continence and potency were preserved, even when ablations involved the urethra
and ejaculatory ducts. Additionally, biopsies taken within the treatment zone showed no evi-
dence of cancer and exhibited characteristics encountered in previous animal studies, including
a well-demarcated ablation and vascular and nervous preservation.14,15
Recent clinical trials have demonstrated similar levels of success in a two-center study by
Valerio et al. after a median follow-up of six months.7 Specifically, 75% (18/24) of patients
exhibited no signs of residual disease, 100% (24/24) were continent, and potency was preserved
in 95% (19/20) of those potent before treatment. Also, no patients had a recto-urethral fistula or
urethral stricture. Prospective studies with higher enrollment are currently underway to confirm
efficacy.8,9,16
Despite the initial encouraging results, relatively little is known about the electrical response
of prostatic tissue to IRE. For a given set of pulse parameters (pulse duration, number, and repeti-
tion rate), the electric field, which is controlled by the applied voltage and electrode spacing, is
the primary factor in defining the spatial distribution of cell death. The macroscopic electric field
controls the microscopic increase in transmembrane potential (TMP) and the induction of nano-
pores. The electric field threshold for cell death has been characterized in several tissue types,
including normal porcine liver (423V/cm),17 normal canine kidneys (575V/cm),18 normal canine
brain (495–510V/cm),19 normal canine prostate (948V/cm),20 and normal human prostate
(1135V/cm).20 Additionally, Neal et al. determined a dynamic conductivity function specific to
normal canine prostate based on intrapulse voltage and current measurements.20
A significant challenge remains in defining the electric field threshold for human prostate
tumors. Here, we utilize contrast-enhanced magnetic resonance imaging (MRI) data from a
human clinical trial7 to reconstruct ablation volumes and predict the electric field threshold.
Specifically, a numerical model was created for the electrodes embedded within the ablation
volume, and the dynamic conductivity function was varied until the calculated current matched
the current measured during the clinical trial. Then, the field threshold was determined by
matching the ablation volume to the volume encompassed by a specific electric field contour.
Our results indicate that the average electric field threshold predicted by the dynamic model
was 506V/cm. Additionally, we found a correlation (r¼0.624) between the field threshold
and pre-treatment prostate-specific antigen (PSA) levels. Taken together, this information could
be used to improve the accuracy of IRE treatment planning algorithms for prostate cancer.
II. RESULTS AND DISCUSSION
Treatment of prostate cancer involves a variety of strategies ranging from active surveil-
lance to radical prostatectomy. Focal therapy with IRE may serve an excellent medium by
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achieving local oncological control with prostatic tissue preservation. Further, patient morbidity
may be reduced, and functional outcomes may be improved compared to other techniques, such
as brachytherapy, cryoablation, and high-intensity focused ultrasound, whose results have been
summarized in Ref. 21. Refer to Sec. IV for a description of the steps for treating patients using
a NanoKnife
VR
(Fig. 1) and simulating the treatments using finite element modeling (Fig. 2).
Determining the electric field threshold for IRE is a vital step in the treatment planning
process. It ensures complete destruction of the targeted zone while preserving as much of the
healthy tissues as possible. In practice, this improves patient outcomes. Our results indicate that
the IRE threshold ranges from 412 to 614V/cm (Table I) with an average of 5066 66V/cm.
These values were obtained using the dynamic conductivity function. For the static model, the
IRE threshold ranges from 277 to 573V/cm with an average of 4226 90V/cm.
FIG. 1. Electrode positioning and pulse protocol for patient P2. The graphical user interface calculates the inter-electrode
spacing and the necessary voltage to achieve 1500V/cm. Voltage and current are reported following treatment. The
NanoKnife delivers pulses in groups of 10 before recharging the capacitor bank, as evident by the periodic drop in voltage
and current. The red arrow indicates the current matched during the derivation of the conductivity functions.
FIG. 2. IRE electrode placement in the 3D reconstruction of the ablation volume for patient P2. Only the ablation volume
was utilized in the finite element simulations. Additionally, the electrodes were treated as cylinders with dimensions dic-
tated by the exposure length, and the insulation and sharp tip were excluded from the simulations.
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Representative electric field and conductivity distributions are shown for patient P3 in Fig.
3. The morphology of the electric field contours for both the static and dynamic models closely
resembles the shape of the ablation volume. However, in the dynamic model, the influence of
electroporation causes the electric field to spread away from the electrodes. This explains the
higher IRE thresholds observed in the dynamic model. The underlying conductivity functions
for all patients are shown in Fig. 4. The step height (rmax) ranges from 0.55 to 1.0 S/m with an
average of 0.726 0.15V/cm.
It should be noted that the electric field thresholds determined for the clinical protocols uti-
lized here in cancerous tissue (506V/cm) are significantly lower than those previously reported
in benign prostate parenchyma (1135V/cm, an average of two trials).20 In addition to the tissue
TABLE I. Treatment characteristics of patients.
Patient No.
PSA
Pre-IRE
Max
voltage (V)
Max
spacing (cm)
Change in
current (A)
Electric field
threshold
(dynamic model)
(V/cm)
Ablation
volume (cm3)
P1 10.03 3000 2.2 11 412 21.08
P2 9.1 3000 2.0 19 436 16.73
P3 8.7 3000 2.1 12 521 11.10
P4 7.8 2850 1.9 11 499 15.82
P5 7.1 2850 1.9 11 512 10.34
P6 6.7 3000 2.0 10 472 19.07
P7 6.5 2700 1.8 10 525 10.05
P8 5.5 2250 1.5 10 614 4.09
P9 3.9 2400 1.6 9 467 10.21
P10 3.8 2100 1.4 6 606 4.63
FIG. 3. Maximum electric field (top) and electric conductivity (bottom) achieved during six pulsing sequences between all
electrode pair combinations for patient P3. The results for static electric conductivity are shown in the left two panes, and
the results for dynamic electric conductivity due to electroporation are shown in the right two panes.
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type, this discrepancy is likely due to a number of compounding factors pertinent to the studies.
The thresholds in Ref. 20 were derived from numerical simulations calibrated to pathologic
lesions three and four weeks post-IRE versus radiologic lesions one week post-IRE. The addi-
tional time between the IRE treatment and lesion evaluation permits a significant lesion resolu-
tion,14 which would require calibrating the electric field threshold to a smaller volume, resulting
in a significantly higher threshold. Furthermore, Ref. 20 used a two-needle electrode array with
a single treatment, and the lesions calibrated in this study used a four-needle electrode array
with six total treatments. The overlap between successive treatments likely reduced the electric
field threshold for cell death, as those regions experienced an elevated number of pulses.22
Statistical correlations between IRE parameters and PSA measures are summarized in
Table II. Pre-treatment PSA demonstrated a potentially strong correlation with the electric field
threshold (r¼0.624, p¼ 0.054). Even though this relationship did not reach statistical signifi-
cance, the analysis was under-powered, most likely due to the sample size (Table II). Pre-
treatment PSA demonstrated a strong significant relationship with the change in the current
(r¼ 0.694; p¼ 0.026) and ablation volume (r¼ 0.730; p¼ 0.017). Additionally, the change in
PSA demonstrated a strong significant relationship with the ablation volume (r¼ 0.843;
p¼ 0.004), and the electric field threshold demonstrated a strong significant relationship with
the ablation volume (r¼0.896; p¼<0.001). The latter may be due to larger regions of over-
lap between successive treatments.
Perhaps, the two most interesting correlations are between the pre-treatment PSA and the
electric field threshold and between the pre-treatment PSA and the change in current (Fig. 5).
Being able to modify the aggressiveness of the treatment protocol according to a priori knowl-
edge of PSA safeguards against under-treatment, which can lead to recurrence. One possible
FIG. 4. Dynamic conductivity function for electroporation utilized in each patient-specific simulation. The height of the
step function was determined parametrically until the calculated current matched the experimental current delivered by the
NanoKnife.
TABLE II. Correlations and p-values.
r (p) Power (%)
Pre-treatment PSA Electric field threshold 0.624 (0.054) 50.9
Pre-treatment PSA Change in current 0.694 (0.026)a 66.6
Pre-treatment PSA Ablation volume 0.730 (0.017)a 75.4
Change in PSA Ablation volume 0.843 (0.004)a 94.2
Electric field threshold Ablation volume 0.896 (<0.001)a 99.9
aStatistical significance p< 0.05.
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explanation for the strong (yet insignificant) correlation between PSA and IRE thresholds is
related to the cell size. According to the Schwan equation23
TMPmax ¼ 1:5E r;
where the maximum transmembrane potential (TMP) across a spherical cell is a function of the
applied electric field (E) and cell radius (r). Larger cells are able to reach a critical TMP for IRE
(e.g., 1 V) with a lower electric field (i.e., larger cells have a lower IRE threshold). Previous stud-
ies have shown that the PSA level is correlated strongly with tumor diagnosis and aggressive-
ness.24 As malignancy is multifactorial, it is not possible to generalize that more aggressive tumors
are comprised of larger cells. Oftentimes, it depends on the type of tumor, and the prostate litera-
ture focuses on links between the cancer progression and Gleason score,25 nuclear morphology,25
and centrosome size.26 The well-studied DU145 and PC3 cell lines do show a dependence of the
cell size on aggressiveness, with the larger PC3 (Ref. 27) cells having a higher metastatic poten-
tial.28 This hypothesis needs to be tested in future work, but it could validate treatment planning
algorithms based on the diameter of cancer cells from biopsy.29 Additionally, it may be advanta-
geous to use the biopsy to create finite element models of multicellular clusters that account for
cell packing density,30 as it has been shown that the electroporation threshold increases with
higher cell packing density.31 These types of biopsy guided treatment planning procedures may
alleviate concerns associated with patient-to-patient variability in response to therapy.
The significant correlation between the pre-treatment PSA and the change in current during
IRE pulse delivery may be explained by the fact that there is also a significant correlation
between the pre-treatment PSA and the ablation volume. Therefore, tumors with a higher pre-
treatment PSA experienced a greater amount of electroporation spatially, which corresponds to
a greater change in current. During IRE of the pancreas, researchers have shown that the
change in tissue resistance was significant in predicting local failure or recurrence, but not over-
all disease free survival.32 For constant voltage electroporation systems, such as the NanoKnife,
FIG. 5. (Top) Correlation between the pre-treatment PSA and the electric field threshold (r¼0.624; p¼ 0.054). (Bottom)
Correlation between the pre-treatment PSA and the change in current (r¼ 0.694; p¼ 0.026).
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the change in current should be inversely proportional to the change in resistance (cur-
rent¼ voltage/resistance). Also of interest is the fact that the change in PSA (pre-treatment
minus post-treatment) was significantly correlated with the ablation volume. Lower post-
treatment PSA scores have been associated with longer disease-free survival following high-
intensity focused ultrasound.33
There are several limitations associated with the numerical models that can be attributed to
either the nature of the clinical procedure or a lack of available data. As mentioned in Sec. IV,
treatments were designed to completely destroy the tumor, and the boundary of the ablation
volume extended into normal prostate tissues. Therefore, the reported electric field thresholds
were likely influenced by healthy cells but provide at the least a conservative estimate for can-
cerous tissues. For a separate study to overcome this limitation, the tumor would need to be
purposely undertreated, which may be possible in treat and resect procedures. Another limita-
tion of this study is that the ablation volumes were measured at one week post-treatment using
MRI. Tissue pathology is required to validate that the measurements are correlated with the
volume of dead cells. It is possible that the ablation volume changes over time and an earlier
or later time point would be more representative of the electric field threshold for cell death.
Finally, major blood vessels,34 nerves, and ducts may distort the electric field.20 These hetero-
geneities should be included in future image reconstructions and simulations to study their
impact on the IRE threshold.
III. CONCLUSION
This investigation provides valuable data regarding the electric field threshold for IRE in
human prostate cancer tissues. Volumetric reconstructions were created from one week post-
treatment MRIs and incorporated into numerical models designed to simulate the electric field
distribution during electroporation. The average electric field threshold that was determined
(5066 66V/cm) is comparable to that of other tissue types [e.g., normal porcine liver (423V/
cm),17 normal canine kidney (575V/cm),18 normal canine brain (495–510V/cm)19], as well as
experiments performed on three-dimensional in vitro tumor models of pancreatic cancer (500V/
cm).35 It was also discovered that there is a potential correlation between the electric field
threshold and the pre-treatment PSA, with higher PSA scores having a lower lethal threshold.
This warrants future investigations into this relationship, as it opens the door for using a physi-
ologic measurement to guide treatment planning.
IV. METHODS
A. Clinical workflow
This is a retrospective analysis of men who underwent therapeutic IRE, and no ID numbers
are assigned to studies granted retrospectively according to local regulations. The results of pre-
vious clinical studies, which were performed with patients’ consent, IRB approval, and Good
Clinical Practices, can be found in Ref. 7. Briefly, patients were treated at Princess Grace
Hospital in London/UK or St. Vincent’s Prostate Cancer Centre in Sydney/Australia. All
patients initially underwent a multi-parametric MRI in addition to demonstrating clinically sig-
nificant prostate cancer through an analysis of their histology. Clinically significant cancer con-
sists of a Gleason pattern 4 and/or a cancer core length 4mm. Patients were treated while
under general anesthesia with deep muscle paralysis using pancuronium bromide. A NanoKnife
generator was used to deliver the IRE treatment. 4–6 needle electrodes were positioned not
more than 2 cm apart transperineally at the margin of the cancer lesion under transrectal ultra-
sound guidance, and the electrode exposure length was set to either 1.5 cm or 2 cm depending
on the size of the tumor. 90 pulses with a pulse length of 70 ls were applied between each
electrode pair. 10 test pulses were initially delivered in order to verify proper electrode place-
ment and parameter selection. If the current was determined to be in the proper range (20–40
A), then the remaining 80 pulses were delivered. An example of the NanoKnife clinical work-
flow is shown in Fig. 1 for patient P2. The operator enters the electrode spacing using a
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graphical user interface, and the system calculates the required voltage to achieve a constant
voltage-to-distance ratio of 1500V/cm. The order of electrode pair activation is determined
from the highest voltage (i.e., largest spacing) to the lowest voltage, and the remaining pulse
parameters can be modified (pulse length and pulse number). The target volume was defined by
MRI and histopathology with a safety margin of 3–5mm. All treatments were performed within
a single session. One week post-treatment, a contrast-enhanced MRI was performed to evaluate
the local effect of the treatment. Additionally, PSA levels were evaluated every three months,
and MRIs were repeated at six months and one year.
B. IRE lesion reconstruction
Three-dimensional reconstructions of the ablation volume were created for 17 patients who
participated in the clinical trial using the one week post-treatment MRIs. The ablation area is
easily visible on post-treatment early scans as the non-enhancing zone on the contrast-enhanced
MR sequence. Additionally, the locations of the electrodes and the apex and base of the pros-
tate were labeled by the study clinicians. The location of the electrodes was determined by
matching the grid reference recorded during the procedure and the margins of the ablation
zone. It is important to note that the prostate gland (pre- and post-treatment) and tumor (pre-
treatment) were also reconstructed but excluded from the simulations. This simplification was
made for several reasons, including the fact that the ablation volume extended beyond the mar-
gin of the tumor into the prostate gland and a lack of available data on the differences in elec-
trical properties between the tumor and the prostate gland.
Of the 17 reconstructions, 7 were omitted from the analysis for various reasons. 2 patients
exhibited large protrusions in their ablation volume which might have resulted from underlying
heterogeneous features (e.g., urethra, bowel, and neurovascular bundle) not included in the sim-
ulation; 3 patients exhibited non-contiguous ablations; 2 patients received an extra treatment for
which the electrode marker data were unavailable. The 10 patients who were analyzed all
received an equivalent energy dose. 9 of the patients received 90 pulses per treatment with a
pulse duration of 70 ls, and 1 patient (JC01) received 70 pulses per treatment with a pulse
duration of 90 ls. As mentioned, based on the electrode spacing, the voltage-to-distance ratio
was 1500V/cm. An exception was patient P1, who had one treatment at 1364V/cm. In this
case, the electrode spacing (2.2 cm) required a larger voltage than available on the NanoKnife
(3000V maximum) to reach 1500V/cm (see Table I).
C. Numerical simulations
A 3D finite element model was developed using COMSOL Multiphysics (version 5.2,
Burlington, MA) to calculate the electric field distribution during IRE therapy. This methodology
has been validated as a means to predict the electric field threshold for reversible electroporation
and IRE.36 The ablation volume was placed inside a cube (7.5 cm), which was large enough to
encompass the surrounding prostate gland (Fig. 2), and the four electrodes were modeled as
stainless steel cylinders [r¼ 2 106 S/m (Ref. 37)] with a height set according to the exposure
length used during treatment. Initially, the electrical conductivity of the tissue (ablation volume
and cube) was set to a static, baseline value (r0¼ 0.284 S/m), which was determined by low-
voltage (50V) pre-pulse current measurements in normal canine prostate.20 It was not possible to
perform similar measurements from the human clinical data included herein, as the NanoKnife
generator does not report pre-pulse currents, and the voltage delivered during the first pulse was
high enough to induce electroporation. Boundary conditions (electric potential and ground) were
applied to the outer surfaces of electrode pairs to mimic the clinical procedure. The electric field
distribution within the tissue (E ¼ r/) was obtained for each electrode pair by solving
r  r0r/ð Þ ¼ 0; (1)
where / is the electric potential. The overall electric field distribution from all six treatments
was defined as a separate variable by taking the maximum values from each pair-based
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combination. Then, the electric field threshold was calculated by performing a volume integra-
tion of the maximum electric field distribution above a certain electric field contour. The value
of the field contour was varied in 1V/cm increments until the volume matched the actual abla-
tion volume.
A second set of simulations were performed with a dynamic electrical conductivity func-
tion to account for the electroporation-induced conductivity increase from the formation of
nanopores
r  r Ejj Þr/ð Þ ¼ 0:ð (2)
This has been shown to be more accurate than the static model in predicting the permeabilized
volume of tissues.38 The conductivity function, r(jEj), was defined as a step function that
increased from r0 to rmax over a transition zone of 800V/cm centered at 500V/cm with a con-
tinuous second derivative (Fig. 3). The characteristics of the transition zone were chosen to
mimic the function developed for normal canine prostate.20 A parametric study was run on
rmax for each patient to match the calculated current to the maximum measured current during
the last set of ten pulses from the first electrode pair activation (see Fig. 1). The first electrode
pair was evaluated to avoid compounding effects from multiple treatments. The current was cal-
culated by integrating the normal current density across a cut plane between the electrodes.
Following the determination of the patient-specific conductivity function, the solution for the
electric field distribution was obtained under these conditions for each electrode pair combina-
tion. Then, an additional variable was created for the overall electric conductivity distribution
from all six treatments by taking the maximum values from each pair-based simulation. Finally,
the electric field threshold was calculated in the same fashion as described earlier.
D. Statistical analysis
Correlations were determined between all variables of interest, including the pre-treatment
PSA, change in current during treatment, change in conductivity during treatment, and the elec-
tric field threshold. Additionally, the correlation between the ablation volume and the change in
PSA was also determined. All statistical analyses were conducted using JMP Pro 11 (Cary,
North Carolina, USA) with a significance level of p  0.05. Due to a low sample size (n¼ 10),
the statistical power for most relationships was very low (<60%). Despite this low power, sig-
nificance relationships were still found.
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